Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.
BACKGROUND: Standard anti-proliferative chemotherapy is relatively ineffective against slowly proliferating androgen-independent prostate cancer cells within metastatic sites. In contrast, the lipophilic cytotoxin thapsigargin, which causes apoptosis by disrupting intracellular free Ca2+ levels, is...
Main Authors: | Denmeade, SR, Jakobsen, C, Janssen, S, Khan, SR, Garrett, E, Lilja, H, Christensen, S, Isaacs, J |
---|---|
格式: | Journal article |
语言: | English |
出版: |
2003
|
相似书籍
-
Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer.
由: Janssen, S, et al.
出版: (2004) -
Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo.
由: Denmeade, SR, et al.
出版: (2003) -
Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug.
由: Janssen, S, et al.
出版: (2006) -
Molecular insights into substrate specificity of prostate specific antigen through structural modeling.
由: Singh, P, et al.
出版: (2009) -
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
由: Lilja, H, et al.
出版: (2008)